Supernus to Host Fourth Quarter and Full Year 2016 Earnings

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
77
Supernus to Host Fourth Quarter and Full Year 2016 Earnings Conference Call

ROCKVILLE, Md., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN ), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial results for the fourth quarter and full year of 2016 after 5:00 PM ET on Tuesday, February 28, 2017.

Jack Khattar, President and Chief Executive Officer, and Greg Patrick, Chief Financial Officer, will host a conference call to present the fourth quarter and full year 2016 results on Wednesday, March 1, 2017 at 9:00 AM ET. Following the presentation, the call will be open for questions.

A live webcast will be available at www.supernus.com .

Please refer to the information below for conference call dial-in information. Callers should dial in approximately 10 minutes prior to the start of the call.

Conference dial-in:           (877) 288-1043
International dial-in:           (970) 315-0267
Conference ID:           70744734
Conference Call Name:           Supernus Pharmaceuticals Fourth Quarter and Full Year 2016 Earnings Conference Call

Following the live call, a replay will be available on the Company's website under the 'Investors' section. The webcast will be available on the Company's website for 60 days following the live call.

About Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company has two marketed products for epilepsy, Oxtellar XR® (extended-release oxcarbazepine) and Trokendi XR® (extended-release topiramate). The Company is also developing several product candidates to address large market opportunities in psychiatry, including SPN-810 for the treatment of impulsive aggression in ADHD patients and SPN-812 for the treatment of ADHD.

CONTACTS: Jack A. Khattar, President and CEO Gregory S. Patrick, Vice President and CFO Supernus Pharmaceuticals, Inc. Tel: (301) 838-2591 or INVESTOR CONTACT: Peter Vozzo Westwicke Partners Office: (443) 213-0505 Mobile: (443) 377-4767 Email: peter.vozzo@westwicke.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Explore Rosanne Cash's Journey in a Unique Exhibition

Updated Category News Views 179

Rosanne Cash Exhibition at the Country Music Hall of Fame The Country Music Hall of Fame and Museum is set to showcase a remarkable exhibition centered on the influential career of Rosanne Cash. This exhibition, titled "Rosanne Cash: Time Is a Mirror," will delve into her extensive journey as an artist, encompassing her evolution as a songwriter and storyteller....

Continue Reading
Transforming Moving Services in Boston: A Commitment to Excellence

Updated Category News Views 91

Transforming Moving Services for Boston Residents Boston's vibrant atmosphere has led to an increased demand for efficient and modern moving solutions. Safe Responsible Movers is dedicated to meeting these needs, offering top-notch services tailored to the specific challenges that both residents and businesses experience. With a solid reputation established over the...

Continue Reading
Endeavour Mining Completes Share Buyback with Significant Volume

Updated Category News Views 196

Endeavour Mining's Recent Share Buyback Announcement Endeavour Mining plc has made a notable step in its commitment to returning value to shareholders through the recent purchase of its ordinary shares. The company has acquired shares from Stifel Nicolaus Europe Limited, marking a significant move in its ongoing buyback program. Aggregated Information on the Share...

Continue Reading
Kristi Vassak Steps Up as COO of Lenox Advisors to Lead Growth

Updated Category News Views 288

Kristi Vassak Takes on Key Role at Lenox Advisors Lenox Advisors, an esteemed wealth management and insurance advisory firm, has appointed Kristi Vassak as Chief Operating Officer. This significant promotion reflects not only her extensive tenure but also her transformative leadership within the company. As a long-term employee who joined the firm in 2005, Vassak has...

Continue Reading
Werewolf Therapeutics Showcases Innovations at Kidney Cancer Summit

Updated Category News Views 134

Werewolf Therapeutics Engages at Kidney Cancer Research Summit WATERTOWN, Mass. — Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), a forward-thinking biopharmaceutical company, is making strides in its mission to revolutionize cancer treatment through conditionally activated therapeutics. This approach aims to empower the body’s immune system...

Continue Reading